Article
Oncology
Gennady Bratslavsky, Stephanie Gleicher, Joseph M. Jacob, Thomas H. Sanford, Oleg Shapiro, Dimitra Bourboulia, Laurie M. Gay, Julie Andrea Elvin, Jo-Anne Vergilio, James Suh, Shakti Ramkissoon, Eric Allan Severson, Jonathan Keith Killian, Alexa Betzig Schrock, Jon H. Chung, Vincent A. Miller, Mehdi Mollapour, Jeffrey S. Ross
Summary: The study found that genomic alteration patterns in collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) differ significantly from clear cell renal cell carcinoma (CCRCC). Targeted therapies for CDC and RMC appear limited, with rare opportunities to target alterations in receptor tyrosine kinase and MTOR pathways. Similarly, the low TMB and absence of MSI-High status in CDC and RMC suggest resistance to immunotherapies.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Review
Biochemistry & Molecular Biology
Franz Sellner, Eva Comperat, Martin Klimpfinger
Summary: Isolated pancreatic metastases of renal cell carcinoma (IsPMRCC) is a rare manifestation of metastatic renal cell carcinoma, and it has unique clinical characteristics such as delayed metastasis, multiple metastases, favorable treatment outcomes, and insensitivity to risk factors associated with volume and growth rate in metastatic surgery.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Matthew Bootsma, Rana R. McKay, Hamid Emamekhoo, Rory M. Bade, Jennifer L. Schehr, Matthew C. Mannino, Anupama Singh, Serena K. Wolfe, Zachery D. Schultz, Jamie Sperger, Wanling Xie, Sabina Signoretti, Christos E. Kyriakopoulos, David Kosoff, Edwin J. Abel, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Michael Bassetti, John Floberg, Menggang Yu, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Toni K. Choueiri, Joshua M. Lang, Shuang G. Zhao
Summary: In this study, liquid biopsies were used to analyze CTC enumeration and the HLA I to PD-L1 ratio in metastatic renal cell carcinoma (mRCC) patients. The results showed that changes in CTC abundance and the HP ratio were significantly associated with treatment response and overall survival. These findings provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
James M. Kilgour, Justin L. Jia, Kavita Y. Sarin
Summary: Basal cell carcinoma is the most common human cancer worldwide, with its molecular basis involving a combination of inherited genetic susceptibility and somatic mutations induced by exposure to UV radiation. This review outlines the known germline and somatic mutations implicated in BCC pathogenesis, along with the affected molecular pathways. Emerging targeted therapeutics offer new opportunities for non-surgical treatment of BCC.
Article
Oncology
Gennady Bratslavsky, Neil Mendhiratta, Michael Daneshvar, James Brugarolas, Mark W. Ball, Adam Metwalli, Katherine L. Nathanson, Phillip M. Pierorazio, Ronald S. Boris, Eric A. Singer, Maria Carlo, Mary B. Daly, Elizabeth P. Henske, Colette Hyatt, Lindsay Middleton, Gloria Morris, Anhyo Jeong, Vivek Narayan, W. Kimryn Rathmell, Ulka Vaishampayan, Bruce H. Lee, Dena Battle, Michael J. Hall, Khaled Hafez, Michael A. S. Jewett, Christina Karamboulas, Sumanta K. Pal, A. Ari Hakimi, Alexander Kutikov, Othon Iliopoulos, W. Marston Linehan, Eric Jonasch, Ramaprasad Srinivasan, Brian Shuch
Summary: A multidisciplinary panel of North American experts was convened to assess opinions on genetic risk assessment in RCC, reaching 30 consensus statements on specific areas related to whom, what, when, and how genetic testing should be performed. Areas requiring further research and discussion were also identified, with plans for a second future meeting.
Review
Oncology
Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega
Summary: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is mainly caused by biallelic loss of the tumor suppressor gene VHL. Dysfunctional degradation of HIF due to VHL loss leads to overaccumulation of HIF, resulting in the activation of genes responsible for cell survival and proliferation in ccRCC. Previous therapies have targeted downstream effectors of HIF, but there is now a focus on interfering with upstream targets.
CANCER TREATMENT REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Weimin Zhong, Hongbin Zhong, Fengling Zhang, Chaoqun Huang, Yao Lin, Jiyi Huang
Summary: This study identified two hypoxia-related molecular subtypes for ccRCC, C1 and C2, with distinct differences in prognosis, immune/stromal scores, and response to immunotherapy and targeted therapy. The C2 subtype exhibited poorer prognosis, higher immune/stromal scores, and greater sensitivity to immunotherapy and targeted therapy, with higher levels of CXCL1/2/3/5/6/8 chemokines. The subtype-specific signature based on differentially expressed genes could independently predict patients' prognosis and assist in personalized prediction of survival probability.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Review
Cell Biology
Yongchang Lai, Fucai Tang, Yapeng Huang, Chengwu He, Chiheng Chen, Jiquan Zhao, Wenqi Wu, Zhaohui He
Summary: Renal cell carcinoma (RCC) is a common urinary system tumor, with clear cell renal cell carcinoma being the most prevalent subtype. Advanced RCC is treated with molecular-targeted drugs and immune checkpoint inhibitors, but resistance may occur due to the dynamic tumor microenvironment and metabolic characteristics. Novel findings on the TME and tumor metabolism in RCC may offer insights for future treatment strategies to overcome resistance.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Carolin Sauter-Meyerhoff, Regina Bohnert, Pascale Mazzola, Viktoria Stuehler, Siarhei Kandabarau, Florian A. Buettner, Stefan Winter, Lisa Herrmann, Steffen Rausch, Joerg Hennenlotter, Falko Fend, Marcus Scharpf, Arnulf Stenzl, Stephan Ossowski, Jens Bedke, Matthias Schwab, Elke Schaeffeler
Summary: Metastatic renal cell carcinoma (RCC) has poor prognosis, and understanding the genetic landscape of distant metastases is crucial for personalized treatment strategies. The somatic mutational composition is significantly associated with cancer-specific survival, and recurrent metastases show higher mutational burden. Synchronous and/or recurrent metastases of individual patients share a high proportion of somatic events even after a time-period >2 yrs, highlighting the importance of somatic profiling for precision medicine in RCC.
Article
Medicine, General & Internal
Attila Mokanszki, Gabor Mehes, Szilvia Lilla Csoma, Sandor Kollar, Yi-Che Chang Chien
Summary: Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine malignancy often associated with sun exposure, with Merkel cell polyomavirus (MCPyV) implicated in its pathogenesis. Genetic differences were identified between MCPyV-positive and -negative MCC cases, with more pathogenic variants found in virus-associated cases. Further research is needed to understand the clinical implications of these findings.
Review
Oncology
Valentina Schiavoni, Roberto Campagna, Valentina Pozzi, Monia Cecati, Giulio Milanese, Davide Sartini, Eleonora Salvolini, Andrea Benedetto Galosi, Monica Emanuelli
Summary: The aim of this review is to discuss novel prognostic and therapeutic markers for clear cell renal cell carcinoma (ccRCC), the most common variant of renal cell carcinoma. ccRCC is characterized by high aggressiveness, invasiveness, and metastatic potential, leading to poor prognosis and high mortality rate. This review provides an overview of the epidemiology, risk factors, established prognostic markers, and recent advances in treatment and biomarker discoveries for ccRCC.
Article
Oncology
Yukari Bando, Junya Furukawa, Tomoaki Terakawa, Kenichi Harada, Nobuyuki Hinata, Yuzo Nakano, Masato Fujisawa
Summary: This study aimed to evaluate the efficacy of molecular targeted therapies following nivolumab in metastatic renal cell carcinoma, with 52 patients selected for treatment outcomes. The results showed that subsequent molecular targeted therapies had a disease control rate of 69.2%, with differences in progression-free survival based on the type of molecular targeted agent used. Regardless of prior nivolumab response, molecular targeted therapies following nivolumab demonstrated comparatively better therapeutic efficacy.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Rohan Garje, Dean Elhag, Hesham A. Yasin, Luna Acharya, Daniel Vaena, Laila Dahmoush
Summary: Chromophobe renal cell carcinoma (chRCC) is characterized by chromosomal aneuploidy, TP53, PTEN, and mitochondrial gene mutations. Limited progress has been seen in chRCC due to its infrequent incidence, with therapeutic approaches often extrapolated from ccRCC treatments.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Clinical Neurology
Yuli Felistia, Patrick Y. Wen
Summary: Although molecular profiling has been useful in the diagnosis and classification of gliomas, targeted therapies still face challenges due to factors such as the blood-brain barrier and tumor heterogeneity. However, progress has been made with the development of specific inhibitors for certain genetic mutations in gliomas.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2023)
Article
Multidisciplinary Sciences
Valentina Cordo, Mariska T. Meijer, Rico Hagelaar, Richard R. de Goeij-de Haas, Vera M. Poort, Alex A. Henneman, Sander R. Piersma, Thang Pham, Koichi Oshima, Adolfo A. Ferrando, Guido J. R. Zaman, Connie R. Jimenez, Jules P. P. Meijerink
Summary: Protein kinase inhibitors are effective cancer treatments, but few targetable kinases have been identified in T cell acute lymphoblastic leukemia. Phosphoproteomics offers insights into pathway activation and signaling networks, providing opportunities for targeted therapy.
NATURE COMMUNICATIONS
(2022)